ATE331510T1 - Verwendung von polyungesättigten fettsäuren zur primären vorbeugung von kardiovaskulären anfällen - Google Patents
Verwendung von polyungesättigten fettsäuren zur primären vorbeugung von kardiovaskulären anfällenInfo
- Publication number
- ATE331510T1 ATE331510T1 AT02023126T AT02023126T ATE331510T1 AT E331510 T1 ATE331510 T1 AT E331510T1 AT 02023126 T AT02023126 T AT 02023126T AT 02023126 T AT02023126 T AT 02023126T AT E331510 T1 ATE331510 T1 AT E331510T1
- Authority
- AT
- Austria
- Prior art keywords
- fatty acids
- polyunsaturated fatty
- seizures
- cardiovascular
- primary prevention
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fats And Perfumes (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT2001MI002384A ITMI20012384A1 (it) | 2001-11-12 | 2001-11-12 | Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE331510T1 true ATE331510T1 (de) | 2006-07-15 |
Family
ID=11448595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02023126T ATE331510T1 (de) | 2001-11-12 | 2002-10-15 | Verwendung von polyungesättigten fettsäuren zur primären vorbeugung von kardiovaskulären anfällen |
Country Status (10)
Country | Link |
---|---|
US (4) | US20030100610A1 (de) |
EP (1) | EP1310249B1 (de) |
JP (1) | JP4731789B2 (de) |
AT (1) | ATE331510T1 (de) |
CY (1) | CY1105119T1 (de) |
DE (1) | DE60212786T2 (de) |
DK (1) | DK1310249T3 (de) |
ES (1) | ES2262741T3 (de) |
IT (1) | ITMI20012384A1 (de) |
PT (1) | PT1310249E (de) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
ITMI20012384A1 (it) * | 2001-11-12 | 2003-05-12 | Quatex Nv | Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori |
GB0403247D0 (en) * | 2004-02-13 | 2004-03-17 | Tillotts Pharma Ag | A pharmaceutical composition |
US8324276B2 (en) | 2005-01-24 | 2012-12-04 | Pronova Biopharma Norge As | Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction |
KR101255650B1 (ko) * | 2005-05-04 | 2013-04-16 | 프로노바 바이오파마 너지 에이에스 | 새로운 dha 유도체 및 약제로서의 용도 |
CN101213281B (zh) * | 2005-05-04 | 2013-03-13 | 普罗诺瓦生物医药挪威公司 | 新的dha衍生物及其作为药物的用途 |
AU2006242914B2 (en) | 2005-05-04 | 2012-02-02 | Pronova Biopharma Norge As | New DHA derivatives and their use as medicaments |
JP5134916B2 (ja) * | 2005-07-08 | 2013-01-30 | 持田製薬株式会社 | 心血管イベント発症予防用組成物 |
CA2570763C (en) * | 2005-07-08 | 2011-08-23 | Mochida Pharmaceutical Co., Ltd. | Composition for preventing onset of cardiovascular events |
US20070104779A1 (en) * | 2005-11-07 | 2007-05-10 | Rongen Roelof M | Treatment with omega-3 fatty acids and products thereof |
CA2634139C (en) * | 2005-12-20 | 2015-06-23 | Cenestra, Llc. | Omega 3 fatty acid formulations |
ES2277557B1 (es) * | 2005-12-21 | 2008-07-01 | Proyecto Empresarial Brudy, S.L. | Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo. |
JP2010508262A (ja) | 2006-11-01 | 2010-03-18 | プロノヴァ バイオファーマ ノルゲ アーエス | 組成物 |
CN101535238A (zh) | 2006-11-01 | 2009-09-16 | 普罗诺瓦生物医药挪威公司 | 作为过氧化物酶体增生物激活受体(PPAR)的活化剂或调节剂的α-取代的ω-3脂质 |
US20080125490A1 (en) * | 2006-11-03 | 2008-05-29 | My Svensson | Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids |
US20100266681A1 (en) * | 2006-11-03 | 2010-10-21 | Anne Kristin Holmeide | Fatty acid alcohols |
US20080306154A1 (en) * | 2006-11-03 | 2008-12-11 | My Svensson | Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids |
US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
MX2011001419A (es) | 2008-08-07 | 2011-05-25 | Prodotti Antibiotici Spa | Tratamiento a largo plazo de deficiencia cardiaca sintomatica. |
JPWO2010018856A1 (ja) * | 2008-08-13 | 2012-01-26 | 持田製薬株式会社 | カンナビノイド受容体関連疾患の予防/改善または治療剤 |
DK2334295T3 (en) | 2008-09-02 | 2017-10-09 | Amarin Pharmaceuticals Ie Ltd | PHARMACEUTICAL COMPOSITION COMPREHENSIVE EICOSAPENTAIC ACID AND NICOTIC ACID AND PROCEDURES FOR USING SAME |
LT3037089T (lt) | 2009-02-10 | 2020-01-10 | Amarin Pharmaceuticals Ireland Limited | Eikozapentaeno rūgšties etilo esteris skirtas hipertriglicidemijai gydydti |
AU2014203034B2 (en) * | 2009-04-29 | 2016-09-15 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
WO2010127103A1 (en) * | 2009-04-29 | 2010-11-04 | Amarin Pharma, Inc. | Stable pharmaceutical composition and methods of using same |
AU2010241567B2 (en) | 2009-04-29 | 2013-10-31 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same |
US8455472B2 (en) | 2009-06-15 | 2013-06-04 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
KR101798670B1 (ko) | 2009-09-23 | 2017-11-16 | 아마린 코포레이션 피엘씨 | 오메가-3 지방산 및 스타틴의 히드록시-유도체를 포함하는 제약 조성물 및 그의 사용 방법 |
NZ600167A (en) * | 2009-10-29 | 2014-06-27 | Acasti Pharma Inc | Concentrated therapeutic phospholipid compositions |
RU2728825C2 (ru) * | 2010-03-04 | 2020-07-31 | Амарин Фармасьютикалз Айрлэнд Лимитед (Апил) | Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания |
ITMI20100961A1 (it) * | 2010-05-27 | 2011-11-28 | Erredue Spa | Miscele ricche in esteri di acidi grassi omega-3, loro composizioni e loro processo di preparazione |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
NZ727980A (en) | 2010-11-29 | 2018-08-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US20120178813A1 (en) | 2011-01-12 | 2012-07-12 | Thetis Pharmaceuticals Llc | Lipid-lowering antidiabetic agent |
WO2012108379A1 (ja) * | 2011-02-07 | 2012-08-16 | 持田製薬株式会社 | 拡張性うっ血性心不全治療剤 |
US9119826B2 (en) | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
US20120302639A1 (en) | 2011-02-16 | 2012-11-29 | Pivotal Therapeutics Inc. | Omega 3 formulations for treatment of risk factors for cardiovascular disease and protection against sudden death |
US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
JP2014506891A (ja) | 2011-02-16 | 2014-03-20 | ピヴォタル セラピューティクス インコーポレイテッド | 心血管疾患(CVD)患者の食事管理のためのω3脂肪酸診断アッセイ |
EP2675446A1 (de) | 2011-02-16 | 2013-12-25 | Pivotal Therapeutics, Inc. | Omega-3-formulierungen mit epa, dha und dpa zur behandlung von risikofaktoren für kardiovaskuläre erkrankungen |
US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
US20140191573A1 (en) * | 2011-09-24 | 2014-07-10 | Kool Koncepts Limited | Energy management system |
US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
EP3348262A1 (de) | 2012-01-06 | 2018-07-18 | Omthera Pharmaceuticals Inc. | Verfahren zur herstellung von dpa-angereicherten zusammensetzungen von mehrfach ungesättigten omega-3-fettsäuren in freier säureform |
EP2800469B1 (de) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Zusammensetzungen und verfahren zur senkung der konzentration an hochsensitivem c-reaktiven protein (hs-crp) bei einer person |
RS61557B1 (sr) | 2012-06-29 | 2021-04-29 | Amarin Pharmaceuticals Ie Ltd | Postupci za smanjenje rizika od kardiovaskularnog događaja kod pacijenta na terapiji statinom primenom etil estra eikozapentaenske kiseline |
US9382187B2 (en) | 2012-07-10 | 2016-07-05 | Thetis Pharmaceuticals Llc | Tri-salt form of metformin |
US8765811B2 (en) | 2012-07-10 | 2014-07-01 | Thetis Pharmaceuticals Llc | Tri-salt form of metformin |
WO2014011895A2 (en) * | 2012-07-11 | 2014-01-16 | Thetis Pharmaceuticals Llc | High solubility acid salts, intravenous dosage forms, nutrition supplementation and methods of use thereof |
WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US9505709B2 (en) | 2014-05-05 | 2016-11-29 | Thetis Pharmaceuticals Llc | Compositions and methods relating to ionic salts of peptides |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US9242008B2 (en) | 2014-06-18 | 2016-01-26 | Thetis Pharmaceuticals Llc | Mineral amino-acid complexes of fatty acids |
DK3157936T3 (en) | 2014-06-18 | 2019-02-04 | Thetis Pharmaceuticals Llc | MINERAL AMINO ACID ACID COMPLEXES OF ACTIVE SUBSTANCES |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
JP6906047B2 (ja) | 2016-06-03 | 2021-07-21 | テティス・ファーマシューティカルズ・エルエルシー | 特異的炎症収束性メディエーターの塩に関連する組成物及び方法 |
US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
WO2019008101A1 (en) | 2017-07-06 | 2019-01-10 | Evonik Technochemie Gmbh | ENTERICALLY COATED SOLID DOSAGE FORM COMPRISING AMINO ACIDS SALTS OF OMEGA-3 FATTY ACIDS |
US11622952B2 (en) | 2017-08-15 | 2023-04-11 | Evonik Operations Gmbh | Tablets with high active ingredient content of omega-3 fatty acid amino acid salts |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
WO2020068163A1 (en) | 2018-09-24 | 2020-04-02 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
JP2022543283A (ja) | 2019-08-08 | 2022-10-11 | エボニック オペレーションズ ゲーエムベーハー | 多価不飽和脂肪酸塩を製造するための下流処理 |
WO2021023857A1 (en) | 2019-08-08 | 2021-02-11 | Evonik Operations Gmbh | Solubility enhancement of poorly soluble actives |
WO2021197969A1 (en) * | 2020-04-01 | 2021-10-07 | Evonik Operations Gmbh | Preparation for use as vasorelaxant |
WO2021197971A1 (en) * | 2020-04-01 | 2021-10-07 | Evonik Operations Gmbh | Preparation for use as antioxidant |
KR20240012390A (ko) | 2021-04-21 | 2024-01-29 | 애머린 파마슈티칼스 아일랜드 리미티드 | 심부전의 위험을 감소시키는 방법 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4805062A (en) | 1986-10-15 | 1989-02-14 | Hitachi, Ltd. | DC circuit breaker and method of commutation thereof |
IT1205043B (it) | 1987-05-28 | 1989-03-10 | Innova Di Ridolfi Flora & C S | Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri |
US4918104A (en) * | 1987-06-16 | 1990-04-17 | Weiss Howard S | Method and composition for increasing the concentration of omega-3 polyunsaturated fatty acids in poultry and poultry eggs and poultry and eggs resulting therefrom |
GB2218984B (en) | 1988-05-27 | 1992-09-23 | Renafield Limited | Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses |
JPH0225447A (ja) | 1988-07-13 | 1990-01-26 | Nippon Oil & Fats Co Ltd | 高度不飽和脂肪酸類の製造方法 |
GB8819110D0 (en) | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
JP2893866B2 (ja) * | 1990-05-25 | 1999-05-24 | 日本油脂株式会社 | 抗不整脈薬 |
GB9125602D0 (en) | 1991-12-02 | 1992-01-29 | Efamol Holdings | Method of preventing reocclusion of arteries |
CN1082909A (zh) | 1993-01-03 | 1994-03-02 | 潘玉珍 | 精制二十二碳六烯酸乙酯复合溶栓、抗痴呆药剂 |
JPH06263634A (ja) * | 1993-03-10 | 1994-09-20 | Sagami Chem Res Center | カルシウム拮抗薬 |
US5760081A (en) * | 1994-05-10 | 1998-06-02 | The General Hospital Corporation | Omega 3 fatty acids in the prevention of ventricular fibrillation |
IT1274734B (it) | 1994-08-25 | 1997-07-24 | Prospa Bv | Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti |
US5541225A (en) | 1994-10-11 | 1996-07-30 | The General Hospital Corporation | α-Linolenic acid and eicosatetraynoic acid in the prevention and treatment of ventricular tachyarrhythmia |
NL9401743A (nl) | 1994-10-20 | 1996-06-03 | Prospa Bv | Zouten van aminoalcoholen en farmaceutische formuleringen die deze bevatten. |
MY118354A (en) | 1995-05-01 | 2004-10-30 | Scarista Ltd | 1,3-propane diol derivatives as bioactive compounds |
PL186618B1 (pl) | 1995-11-28 | 2004-02-27 | Braun Melsungen Ag | Izotoniczna emulsja lipidowa do podawania pozajelitowego i jej zastosowanie |
IT1277953B1 (it) | 1995-12-21 | 1997-11-12 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per |
JPH10139664A (ja) * | 1996-11-12 | 1998-05-26 | Sagami Chem Res Center | 抗不整脈薬 |
JPH11239464A (ja) * | 1997-06-16 | 1999-09-07 | Nippon Suisan Kaisha Ltd | 運動時の危険因子除去能を有する組成物 |
DE69842121D1 (de) | 1997-12-10 | 2011-03-17 | Cyclosporine Therapeutics Ltd | Omega-3 fettsäure enthaltende pharmazeutische zusammensetzungen |
DE19855426A1 (de) * | 1998-12-02 | 2000-06-08 | Wolfgang Langhoff | Mittel zur Therapie und Prophylaxe von rheumatisch-arthritischen Erkrankungen und zur Prophylaxe von cardiovaskulären Erkrankungen |
IT1308613B1 (it) | 1999-02-17 | 2002-01-09 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella prevenzione di eventi cardiovascolari. |
AUPQ480399A0 (en) | 1999-12-22 | 2000-02-03 | Commonwealth Scientific And Industrial Research Organisation | Unsaturated fatty acids and their uses in therapy |
AU3846801A (en) * | 2000-02-16 | 2001-08-27 | Brigham & Womens Hospital | Aspirin-triggered lipid mediators |
DK1157692T3 (da) * | 2000-05-22 | 2006-02-06 | Pro Aparts Investimentos E Con | Sammensætning af fedtsyrer indeholdende mindst 80 vægt-% EPA og DHA, derivater deraf og farmaceutisk anvendelse deraf |
ITMI20010129A1 (it) | 2001-01-25 | 2002-07-25 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco |
JP4337273B2 (ja) * | 2001-04-20 | 2009-09-30 | 日本水産株式会社 | 基礎代謝増進剤 |
EP1279400A1 (de) * | 2001-07-25 | 2003-01-29 | Target Hit sa | Änderung der Fettsäurezusammensetzung Organ- und Gewebe-Zellmembranen |
AU784852B2 (en) * | 2001-08-10 | 2006-07-06 | Mars, Incorporated | Canine support diet |
ITMI20012384A1 (it) | 2001-11-12 | 2003-05-12 | Quatex Nv | Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori |
US20030144219A1 (en) | 2001-11-15 | 2003-07-31 | Phinney Stephen Dodge | Formulations and methods for treatment or amelioration of inflammatory conditions |
WO2008066745A1 (en) | 2006-11-22 | 2008-06-05 | Reliant Pharmaceuticals, Inc. | Prophlyaxis and treatment of atrial fibrillation with omega-3 fatty acids |
-
2001
- 2001-11-12 IT IT2001MI002384A patent/ITMI20012384A1/it unknown
-
2002
- 2002-10-15 DK DK02023126T patent/DK1310249T3/da active
- 2002-10-15 ES ES02023126T patent/ES2262741T3/es not_active Expired - Lifetime
- 2002-10-15 AT AT02023126T patent/ATE331510T1/de active
- 2002-10-15 EP EP02023126A patent/EP1310249B1/de not_active Revoked
- 2002-10-15 PT PT02023126T patent/PT1310249E/pt unknown
- 2002-10-15 DE DE60212786T patent/DE60212786T2/de not_active Expired - Lifetime
- 2002-10-25 JP JP2002310878A patent/JP4731789B2/ja not_active Expired - Fee Related
- 2002-10-28 US US10/281,208 patent/US20030100610A1/en not_active Abandoned
-
2004
- 2004-02-17 US US10/778,182 patent/US7553870B2/en active Active
-
2006
- 2006-07-31 CY CY20061101067T patent/CY1105119T1/el unknown
-
2007
- 2007-11-19 US US11/984,485 patent/US7619002B2/en not_active Expired - Fee Related
-
2009
- 2009-09-29 US US12/568,997 patent/US8648061B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CY1105119T1 (el) | 2009-11-04 |
EP1310249A1 (de) | 2003-05-14 |
US20100016428A1 (en) | 2010-01-21 |
ES2262741T3 (es) | 2006-12-01 |
PT1310249E (pt) | 2006-09-29 |
US20030100610A1 (en) | 2003-05-29 |
JP2003146874A (ja) | 2003-05-21 |
US20040162349A1 (en) | 2004-08-19 |
US20080269331A1 (en) | 2008-10-30 |
ITMI20012384A1 (it) | 2003-05-12 |
DE60212786T2 (de) | 2007-06-28 |
DE60212786D1 (de) | 2006-08-10 |
DK1310249T3 (da) | 2006-09-25 |
EP1310249B1 (de) | 2006-06-28 |
US7553870B2 (en) | 2009-06-30 |
US7619002B2 (en) | 2009-11-17 |
JP4731789B2 (ja) | 2011-07-27 |
US8648061B2 (en) | 2014-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE331510T1 (de) | Verwendung von polyungesättigten fettsäuren zur primären vorbeugung von kardiovaskulären anfällen | |
DE69622722D1 (de) | Fette enthaltende Ernährungszusammensetzung zur Behandlung des Stoffwechselssyndroms | |
DK1157692T3 (da) | Sammensætning af fedtsyrer indeholdende mindst 80 vægt-% EPA og DHA, derivater deraf og farmaceutisk anvendelse deraf | |
HK1058883A1 (en) | Use of coenzyme q (ubiquinone) and eicosapentaenoic acid (epa) for the treatment of non-hodgkin's lymphoma and psychiatric or neurological disorders. | |
TR199900786T2 (xx) | Eykoza penta enoik asit ve/veya stearidonik asit i�eren farmas�tik terkipler. | |
DK1152755T3 (da) | Essentielle fedtsyrer til forebyggelse af cardiovaskulære tilfælde | |
EP0292846A3 (en) | A process for the extraction of polyunsaturated fatty acid esters from fish oils and pharmaceutical and/or dietetic compositions containing said esters | |
EP0302482A3 (de) | Freie Fettsäuren zur Behandlung oder Prophylaxe von rheumatoider Arthritis | |
DK1121115T4 (da) | PUFA-tilskud | |
ATE75502T1 (de) | Verfahren zur herstellung von polyungesaettigten fettsaeuren. | |
UA89207C2 (ru) | Применение длинноцепочечных полиненасыщенных жирных кислот для получения жидкой питательной смеси для кормления детей | |
WO2004078166A3 (en) | Use of omega-3-fatty acids in the treatment of diabetic patients | |
KR940018091A (ko) | 불포화 지방산을 포함하는 처방 | |
DK0623019T3 (da) | Medikamenter på basis af docosahexaensyre som midler mod blodpladeaggregation og mod cerebral mangel på essentielle fedtsyr | |
PT804411E (pt) | Analogos sinteticos de acidos gordos poli-insaturados | |
AU2441400A (en) | Stabilized lipidic composition, method for the preparation thereof and nutritional product containing the same | |
FR2843124B1 (fr) | Procede de preparation d'acides gras polyinsatures libres et de leurs metabolites d'oxydation | |
RU93049092A (ru) | Лечение жирными кислотами | |
DE60329588D1 (de) | Verwendung von epa and dha zur sekundären prevention von schlaganfällen | |
NO932984L (no) | Fettsyrebehandling | |
NZ304924A (en) | hybridised triglycerides | |
MY129218A (en) | Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1310249 Country of ref document: EP |